Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Theriva Biologics, Inc. Common Stock (NY:TOVX)

0.4060 +0.0040 (+1.00%)
Official Closing Price Updated: 8:00 PM EDT, Oct 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Theriva Biologics, Inc. Common Stock

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Wednesday?
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
Wondering what's happening in today's after-hours session?
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
These stocks are moving in today's after hours session
Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
On Thursday, there are stocks with unusual volume. Let's take a look.
These stocks have an unusual volume in today's session 
Via Chartmill
This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
 
Via Benzinga
Theriva Biologics Shares Plunge After Pricing $7.5M Offering: Retail Sentiment Still Strong
The offering comes on the heels of encouraging data from the Virage Phase 2b trial, which demonstrated significant improvements in overall survival and duration of response for patients receiving... 
Via Stocktwits
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
Via ACCESS Newswire
Wondering what's happening in today's pre-market session?
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
US Stocks To Open Higher On Shortened Trading Day: Santa Claus Rally Period Officially Begins, Says Analyst
U.S. stock futures advanced on Tuesday, head of a shortened trading session owning to Christmas-eve. The stock market will shut at 1 p.m. ET. 
Via Benzinga
Why Carbon Revolution Shares Are Trading Higher By Around 62%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
What's Going On With Theriva Biologics Stock Friday?
Theriva stock is trading higher after the company announced it was selected as a finalist for Merck's KGaA's EMEA Advance Biotech Grant. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Nasdaq Moves Lower; Levi Strauss Shares Slide
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Crude Oil Jumps Over 4%; US Services PMI Revised Lower
 
Via Benzinga
Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients
Theriva Biologics announces DSMC approval to proceed to Cohort 3 in its SYN-004 trial for aGVHD prevention. No adverse events linked to SYN-004 were reported, supporting its continued development. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.